These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30801965)

  • 21. Design and synthesis of potent Gram-negative specific LpxC inhibitors.
    Mansoor UF; Vitharana D; Reddy PA; Daubaras DL; McNicholas P; Orth P; Black T; Siddiqui MA
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1155-61. PubMed ID: 21273067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
    Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR
    J Biol Chem; 2000 Apr; 275(15):11002-9. PubMed ID: 10753902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
    Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
    Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
    Liu F; Ma S
    Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, Synthesis, and Biological Evaluation of Vanillin Hydroxamic Acid Derivatives as Novel Peptide Deformylase Inhibitors.
    Gao J; Qiu S; Liang L; Hao Z; Zhou Q; Wang F; Mou J; Lin Q
    Curr Comput Aided Drug Des; 2018; 14(1):95-101. PubMed ID: 28606047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
    Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
    J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity.
    Yamada Y; Takashima H; Walmsley DL; Ushiyama F; Matsuda Y; Kanazawa H; Yamaguchi-Sasaki T; Tanaka-Yamamoto N; Yamagishi J; Kurimoto-Tsuruta R; Ogata Y; Ohtake N; Angove H; Baker L; Harris R; Macias A; Robertson A; Surgenor A; Watanabe H; Nakano K; Mima M; Iwamoto K; Okada A; Takata I; Hitaka K; Tanaka A; Fujita K; Sugiyama H; Hubbard RE
    J Med Chem; 2020 Dec; 63(23):14805-14820. PubMed ID: 33210531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532.
    Ushiyama F; Takashima H; Matsuda Y; Ogata Y; Sasamoto N; Kurimoto-Tsuruta R; Ueki K; Tanaka-Yamamoto N; Endo M; Mima M; Fujita K; Takata I; Tsuji S; Yamashita H; Okumura H; Otake K; Sugiyama H
    Bioorg Med Chem; 2021 Jan; 30():115964. PubMed ID: 33385955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptide deformylase inhibitors with non-peptide scaffold: synthesis and structure-activity relationships.
    Lee SK; Choi KH; Lee SJ; Lee JS; Park JY; Kim BM; Lee BJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):133-6. PubMed ID: 21146987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The inhibitory and binding studies of methyl-sulfone hydroxamate based inhibitors against LpxC from drug resistant Moraxella catarrhalis using biophysical, biochemical and in silico approaches.
    Sharma A; Kumar V; Pratap S; Kumar P
    Int J Biol Macromol; 2018 Oct; 118(Pt B):1747-1762. PubMed ID: 30017978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.
    Warmus JS; Quinn CL; Taylor C; Murphy ST; Johnson TA; Limberakis C; Ortwine D; Bronstein J; Pagano P; Knafels JD; Lightle S; Mochalkin I; Brideau R; Podoll T
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2536-43. PubMed ID: 22401863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibacterial agents that inhibit lipid A biosynthesis.
    Onishi HR; Pelak BA; Gerckens LS; Silver LL; Kahan FM; Chen MH; Patchett AA; Galloway SM; Hyland SA; Anderson MS; Raetz CR
    Science; 1996 Nov; 274(5289):980-2. PubMed ID: 8875939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LpxC inhibitors: a patent review (2010-2016).
    Kalinin DV; Holl R
    Expert Opin Ther Pat; 2017 Nov; 27(11):1227-1250. PubMed ID: 28742403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Para-(benzoyl)-phenylalanine as a potential inhibitor against LpxC of Leptospira spp.: homology modeling, docking, and molecular dynamics study.
    Pradhan D; Priyadarshini V; Munikumar M; Swargam S; Umamaheswari A; Bitla A
    J Biomol Struct Dyn; 2014; 32(2):171-85. PubMed ID: 23383626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design.
    Lee CJ; Liang X; Chen X; Zeng D; Joo SH; Chung HS; Barb AW; Swanson SM; Nicholas RA; Li Y; Toone EJ; Raetz CR; Zhou P
    Chem Biol; 2011 Jan; 18(1):38-47. PubMed ID: 21167751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC.
    Barb AW; Leavy TM; Robins LI; Guan Z; Six DA; Zhou P; Hangauer MJ; Bertozzi CR; Raetz CR
    Biochemistry; 2009 Apr; 48(14):3068-77. PubMed ID: 19256534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent inhibitors of LpxC for the treatment of Gram-negative infections.
    Brown MF; Reilly U; Abramite JA; Arcari JT; Oliver R; Barham RA; Che Y; Chen JM; Collantes EM; Chung SW; Desbonnet C; Doty J; Doroski M; Engtrakul JJ; Harris TM; Huband M; Knafels JD; Leach KL; Liu S; Marfat A; Marra A; McElroy E; Melnick M; Menard CA; Montgomery JI; Mullins L; Noe MC; O'Donnell J; Penzien J; Plummer MS; Price LM; Shanmugasundaram V; Thoma C; Uccello DP; Warmus JS; Wishka DG
    J Med Chem; 2012 Jan; 55(2):914-23. PubMed ID: 22175825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibacterial activities and characterization of novel inhibitors of LpxC.
    Clements JM; Coignard F; Johnson I; Chandler S; Palan S; Waller A; Wijkmans J; Hunter MG
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1793-9. PubMed ID: 12019092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure of the metal-dependent deacetylase LpxC from Yersinia enterocolitica complexed with the potent inhibitor CHIR-090 .
    Cole KE; Gattis SG; Angell HD; Fierke CA; Christianson DW
    Biochemistry; 2011 Jan; 50(2):258-65. PubMed ID: 21171638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay.
    Langsdorf EF; Malikzay A; Lamarr WA; Daubaras D; Kravec C; Zhang R; Hart R; Monsma F; Black T; Ozbal CC; Miesel L; Lunn CA
    J Biomol Screen; 2010 Jan; 15(1):52-61. PubMed ID: 20019290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.